Published in
Elsevier, European Journal of Cancer, (88), p. 1-9, 2018
DOI: 10.1016/j.ejca.2017.10.029
Links
Tools
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Journal article published in 2017 by
Sara Valpione,
Gabriela Gremel,
P. A. Mundra,
P. Middlehurst,
Elena Galvani,
Maria Romina Girotti,
Rebecca J. Lee,
G. Garner,
Nathalie Dhomen 
,
Paul C. Lorigan,
Richard Marais
,
Paul C. Lorigan,
Richard Marais
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Tumour burden is a prognostic biomarker in metastatic melanoma. However, tumour burden is difficult to measure and there are currently no reliable surrogate biomarkers to easily and reliably determine it. The aim of this study was to assess the potential of plasma total cell free DNA as biomarker of tumour burden and prognosis in metastatic melanoma patients.